Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Yisheng Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The alliance is aimed at co-developing a combination therapy of YS-ON-001\/002 and Tavo-201\/203 for cancer treatment.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"YuanBio Venture Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Tavotek Biotherapeutics

    Menu

    Tavotek Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tavotek Biotherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars

              Details:

              The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody drugs (Tavo111, Tavo103, and Tavo101) developed by the company based on its TavoPrecise antibody platform.

              Lead Product(s): Tavo111

              Therapeutic Area: Oncology Product Name: Tavo111

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: YuanBio Venture Capital

              Deal Size: $20.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing March 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tavotek Biotherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform

              Details:

              The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.

              Lead Product(s): Bispecific antibodies

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Recipient: Genmab

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tavotek Biotherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The alliance is aimed at co-developing a combination therapy of YS-ON-001/002 and Tavo-201/203 for cancer treatment.

              Details:

              The objective of the alliance is to co-develop a combination therapy of involving Yisheng's & Tavotek's lead assets YS-ON-001/002 and Tavo-201/203 for cancer treatment.

              Lead Product(s): YS-ON-001,YS-ON-002,Tavo-201

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Yisheng Biopharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY